soul trial oral semaglutide cardiovascular outcomes 2024 nejm 🧿 is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM Cardiovascular outcomes of semaglutide and

The published mechanism studies are predominantly on semaglutide and liraglutide, but the GLP-1 receptor pathway is shared by all GLP-1 receptor agonists including liraglutide, dulaglutide, semaglutide, and tirzepatide

Another study from Food Science & Nutrition found that Eriomin lemon fruit extract increased blood levels of GLP-1 but didn't help to decrease weight

Pharmacological inhibition of complement C5aC5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis

Acute pancreatitis was reported in all 11 studies, with ARD values typically below 0.3% and overall event rates below 1%, suggesting no meaningful increase in risk compared with placebo